Clinical Research Directory
Browse clinical research sites, groups, and studies.
Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis
Sponsor: Al-Azhar University
Summary
Nocturnal Enuresis (NE) is defined as the involuntary passage of urine during sleep past the age of usual control, which is considered a developmental age of 5 to 7 years. NE is a common problem that causes distress to both children and their families. It has an adverse impact on behavior and social life, affects self-esteem, and can result in poor emotional well-being. In Egypt, the prevalence of NE in primary school children is about 15.4%. The family history was seen to have had a markedly significant impact on the occurrence of NE in the studied children. The mainstay of treatment is urotherapy with information and psychoeducation about normal lower urinary tract function, the underlying cause of MNE, disturbed bladder dysfunction in the child with NMNE, and instructions about therapeutic strategies. Alarm therapy and desmopressin are effective in randomized trials. Children with NMNE first need treatment of the underlying daytime functional bladder problem before treatment of nocturnal enuresis.
Official title: Predictors of Success and Relapse After Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis
Key Details
Gender
All
Age Range
7 Years - 14 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2024-02-23
Completion Date
2024-05-12
Last Updated
2024-04-23
Healthy Volunteers
No
Conditions
Interventions
Desmopressin
Desmopressin is a synthetic analogue of ADH released by the posterior pituitary gland that reduces urine production by increasing water reabsorption by the collecting tubules.
Locations (1)
Alazhar university
Asyut, Egypt